1 terminated. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Terminated 1 |
Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis BG00002 (natalizumab), interferon beta-1a, glatiramer acetate - Relapsing Remitting Multiple Sclerosis | Phase 3 | Terminated | Biogen | 84 | 2010-03-01 | 2014-09-03 |
Multiple Sclerosis, Relapsing-Remitting (1)
Autoimmune Diseases (1) · Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Multiple Sclerosis (1) · Nervous System Diseases (1)
Glatiramer Acetate (1) · Interferon beta-1a (1) · Natalizumab (1)
Biogen (1)
Australia (1) · Canada (1) · Czechia (1) · Finland (1) · France (1) · Hungary (1) · Italy (1) · Latvia (1) · Poland (1) · Slovenia (1) · Spain (1) · Sweden (1) · United States (1)